Inactive Instrument

Novo Nordisk A/S Stock Xetra

Equities

DK0060102614

Pharmaceuticals

End-of-day quote Xetra
- EUR - Intraday chart for Novo Nordisk A/S

Financials

Sales 2024 * 287B 41.32B 38.48B Sales 2025 * 347B 49.89B 46.45B Capitalization 3,879B 558B 520B
Net income 2024 * 103B 14.86B 13.84B Net income 2025 * 125B 18.03B 16.78B EV / Sales 2024 * 13.7 x
Net Debt 2024 * 53.94B 7.76B 7.23B Net Debt 2025 * 12.36B 1.78B 1.66B EV / Sales 2025 * 11.2 x
P/E ratio 2024 *
39 x
P/E ratio 2025 *
31.9 x
Employees -
Yield 2024 *
1.37%
Yield 2025 *
1.57%
Free-Float 70.17%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 58 90-12-31
Director of Finance/CFO 53 98-12-31
Chief Tech/Sci/R&D Officer - 15-09-30
Members of the board TitleAgeSince
Director/Board Member 63 15-03-18
Chairman 61 17-03-22
Director/Board Member 68 18-02-28
More insiders
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
More about the company